16-01-2013

Horizon Discovery Ltd announced it has signed a research service collaboration agreement with Boehringer Ingelheim. Horizon will support Boehringer Ingelheim’s oncology programs by using its Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead ...

more

Ablynx to receive €1 million milestone payment

26-04-2012

Ablynx announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration signed ...

more

22-03-2012

Ablynx announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. The extension which will run until September 2014, will allow all the ...

more

03-02-2012

Ablynx announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. The Nanobody development candidate is designed to interfere with the function of ...

more

25-01-2012

Priaxon and Boehringer Ingelheim will prolongate their research and development collaboration on mdm2/p53 inhibitors for the treatment of cancer.The companies will continue working jointly to identify and advance drug candidates into pre-clinical development. Thereafter, Boehringer Ingelheim ...

more

22-09-2011

Nuevolution A/S announced that it has entered into collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics® drug discovery technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened to discover and advance ...

more

21-09-2011

4-Antibody AG announced the successful completion of a second milestone in its ongoing collaboration with Boehringer Ingelheim. This second milestone triggered an undisclosed fee payment. 4-Antibody’s R&D collaboration with Boehringer Ingelheim commenced in early 2010 and is a long-term ...

more

22-08-2011

Evotec AG announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec. The milestone was achieved for the identification and selection of a compound to be advanced into pre-clinical development within an oncology ...

more

12-08-2011

Boehringer Ingelheim and ProBioGen AG announced that they have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) ...

more

28-06-2011

Ablynx announced that it has earned a €5 million milestone payment following Boehringer Ingelheim's decision to initiate development with the lead Nanobody candidate that was selected in May 2010. In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing ...

more